ID M249 AC CVCL_D755 DR EFO; EFO_0022586 DR ArrayExpress; E-MTAB-5493 DR cancercelllines; CVCL_D755 DR Cosmic; 1425353 DR Cosmic; 1459652 DR Cosmic; 1545618 DR Cosmic; 1665014 DR Wikidata; Q54903562 RX PubMed=20406486; RX PubMed=20689758; RX PubMed=22194965; RX PubMed=22515704; RX PubMed=24735930; RX PubMed=29229836; CC Doubling time: 21.2 hours (PubMed=20406486). CC Sequence variation: Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Homozygous (PubMed=20406486; PubMed=22194965). CC Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965). CC Omics: Transcriptomics; RNAseq. DI NCIt; C3224; Melanoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) SX Sex unspecified AG Age unspecified CA Cancer cell line DT Created: 22-10-12; Last updated: 10-04-25; Version: 16 CH CVCL_EI93 ! M249 R4 // RX PubMed=20689758; DOI=10.1593/neo.10414; PMCID=PMC2915408; RA Tap, William Douglas RA Gong, Ke-Wei RA Dering, Judy RA Tseng, Yiou RA Ginther, Charles RA Pauletti, Giovanni RA Glaspy, John A. RA Essner, Richard RA Bollag, Gideon RA Hirth, Peter RA Zhang, Chao RA Slamon, Dennis Joseph RT "Pharmacodynamic characterization of the efficacy signals due to RT selective BRAF inhibition with PLX4032 in malignant melanoma."; RL Neoplasia 12:637-649(2010). // RX PubMed=22194965; DOI=10.1371/journal.pone.0028973; PMCID=PMC3237573; RA Atefi, Mohammad RA von Euw, Erika Maria RA Attar, Narsis RA Ng, Charles RA Chu, Connie RA Guo, De-Liang RA Nazarian, Ramin RA Chmielowski, Bartosz RA Glaspy, John A. RA Comin-Anduix, Begonya RA Mischel, Paul Salomon RA Lo, Roger S. RA Ribas, Antoni RT "Reversing melanoma cross-resistance to BRAF and MEK inhibitors by RT co-targeting the AKT/mTOR pathway."; RL PLoS ONE 6:e28973.1-e28973.12(2011). // RX PubMed=22515704; DOI=10.1186/1476-4598-11-22; PMCID=PMC3444881; RA von Euw, Erika Maria RA Atefi, Mohammad RA Attar, Narsis RA Chu, Connie RA Zachariah, Sybil RA Burgess, Barry L. RA Mok, Stephen RA Ng, Charles RA Wong, Deborah Jean Lee RA Chmielowski, Bartosz RA Lichter, David I. RA Koya, Richard C. RA McCannel, Tara A. RA Izmailova, Elena RA Ribas, Antoni RT "Antitumor effects of the investigational selective MEK inhibitor RT TAK733 against cutaneous and uveal melanoma cell lines."; RL Mol. Cancer 11:22.1-22.9(2012). // RX PubMed=29229836; DOI=10.1073/pnas.1712064115; PMCID=PMC5748184; RA Su, Ya-Peng RA Wei, Wei RA Robert, Lidia RA Xue, Min RA Tsoi, Jennifer RA Garcia-Diaz, Angel RA Homet Moreno, Blanca RA Kim, Jungwoo RA Ng, Rachel Hin-Ying RA Lee, Jihoon W. RA Koya, Richard C. RA Comin-Anduix, Begonya RA Graeber, Thomas G. RA Ribas, Antoni RA Heath, James Richard RT "Single-cell analysis resolves the cell state transition and signaling RT dynamics associated with melanoma drug-induced resistance."; RL Proc. Natl. Acad. Sci. U.S.A. 114:13679-13684(2017). // RX PubMed=20406486; DOI=10.1186/1479-5876-8-39; PMCID=PMC2876068; RA Sondergaard, Jonas Norskov RA Nazarian, Ramin RA Wang, Qi RA Guo, De-Liang RA Hsueh, Teli RA Mok, Stephen RA Sazegar, Hooman RA MacConaill, Laura Eleanor RA Barretina, Jordi Ginesta RA Kehoe, Sarah M. RA Attar, Narsis RA von Euw, Erika Maria RA Zuckerman, Jonathan E. RA Chmielowski, Bartosz RA Comin-Anduix, Begonya RA Koya, Richard C. RA Mischel, Paul Salomon RA Lo, Roger S. RA Ribas, Antoni RT "Differential sensitivity of melanoma cell lines with BRAFV600E RT mutation to the specific Raf inhibitor PLX4032."; RL J. Transl. Med. 8:39.1-39.11(2010). // RX PubMed=24735930; DOI=10.1186/1476-4598-13-83; PMCID=PMC4021505; RA Lassen, Amanda RA Atefi, Mohammad RA Robert, Lidia RA Wong, Deborah Jean Lee RA Cerniglia, Michael RA Comin-Anduix, Begonya RA Ribas, Antoni RT "Effects of AKT inhibitor therapy in response and resistance to BRAF RT inhibition in melanoma."; RL Mol. Cancer 13:83.1-83.14(2014). //